STOCK TITAN

Tyra Biosciences, Inc. - $TYRA STOCK NEWS

Welcome to our dedicated page for Tyra Biosciences news (Ticker: $TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tyra Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tyra Biosciences's position in the market.

Rhea-AI Summary
Tyra Biosciences to present TYRA-300 for achondroplasia at ASBMR and ASHG annual meetings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
Tyra Biosciences to participate at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Summary
Tyra Biosciences, Inc. (TYRA) reports a strong cash position of $232.4 million as of Q2 2023. The company's TYRA-300 receives Orphan Drug Designation for achondroplasia, and the SURF301 Phase 1/2 oncology study remains on target with ongoing enrollment in Part B. Additionally, the TYRA-200 Phase 1 study is on track, with the first patient to be dosed in 2H 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
Rhea-AI Summary
Tyra Biosciences, Inc. has received Orphan Drug Designation from the FDA for its lead precision medicine program, TYRA-300, for the treatment of achondroplasia, the most common form of dwarfism. TYRA-300 is an oral FGFR3 selective inhibitor that aims to address height and long-term health complications associated with achondroplasia. The company plans to submit an IND to the FDA for a Phase 2 study in pediatric achondroplasia in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.04%
Tags
conferences
Tyra Biosciences, Inc.

Nasdaq:TYRA

TYRA Rankings

TYRA Stock Data

1.00B
15.63M
5.34%
82.09%
5.38%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CARLSBAD

About TYRA

tyra biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.